Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8 associated disorders

US7910107B2 · kind B2 · utility

Assignees

• Wyeth, LLC · US
• The Trustees of the University of Pennsylvania · US

Inventors

• Frank S. Walsh · Via Enrico Fermi, US
• Margaret M. Zaleska · Narberth, US
• David S. Howland · Exton, US
• Erika L. F. Holzbaur-Howland · Yardley, US
• Lioudmila Tchistiakova · Andover, US
• Riyez Karim · North Andover, US
• Pamela Kelley · Reading, US
• Xiang-Yang Tan · Reading, US
• Seung Poon Kwak · Ewing, US
• Karen Wallace · Dorpsstraat, US
• Nicholas Weber · Smethport, US
• Menelas N. Pangalos · Pennington, US

Key dates

• Filing date: Jul 24, 2009
• Grant date: Mar 22, 2011
• Expiry date: Jul 24, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.